ECSP12011930A - Nuevos compuestos de espiropiperidina - Google Patents

Nuevos compuestos de espiropiperidina

Info

Publication number
ECSP12011930A
ECSP12011930A ECSP12011930A ECSP12011930A EC SP12011930 A ECSP12011930 A EC SP12011930A EC SP12011930 A ECSP12011930 A EC SP12011930A EC SP12011930 A ECSP12011930 A EC SP12011930A
Authority
EC
Ecuador
Prior art keywords
spyropiperidine
compounds
new
compound
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Chafiq Hamdouchi
Pranab Maiti
Jayana Pankaj Lineswala
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384775&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011930(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP12011930A publication Critical patent/ECSP12011930A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de la fórmula:o una sal del mismo farmacéuticamente aceptable así como también una composición farmacéutica, y un método para tratar la diabetes.
ECSP12011930 2009-11-30 2012-05-20 Nuevos compuestos de espiropiperidina ECSP12011930A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26518109P 2009-11-30 2009-11-30

Publications (1)

Publication Number Publication Date
ECSP12011930A true ECSP12011930A (es) 2012-07-31

Family

ID=43384775

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011930 ECSP12011930A (es) 2009-11-30 2012-05-20 Nuevos compuestos de espiropiperidina

Country Status (25)

Country Link
US (1) US8822486B2 (es)
EP (1) EP2507228B1 (es)
JP (1) JP5709889B2 (es)
KR (1) KR101410103B1 (es)
CN (1) CN102648195B (es)
AR (1) AR078948A1 (es)
AU (1) AU2010324987B2 (es)
BR (1) BR112012012903A2 (es)
CA (1) CA2781292C (es)
CL (1) CL2012001321A1 (es)
CR (1) CR20120296A (es)
DO (1) DOP2012000139A (es)
EA (1) EA020507B1 (es)
EC (1) ECSP12011930A (es)
ES (1) ES2526568T3 (es)
GT (1) GT201200164A (es)
IL (1) IL219594A0 (es)
MA (1) MA33840B1 (es)
MX (1) MX2012006233A (es)
NZ (1) NZ600203A (es)
PE (1) PE20121474A1 (es)
TN (1) TN2012000248A1 (es)
TW (1) TW201141866A (es)
WO (1) WO2011066183A1 (es)
ZA (1) ZA201203055B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
JP5002077B2 (ja) 2009-12-25 2012-08-15 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソチアゾール誘導体
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
JP5420796B2 (ja) 2011-04-27 2014-02-19 持田製薬株式会社 新規３−ヒドロキシイソチアゾール１−オキシド誘導体
AU2012248627A1 (en) 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
CA2905726C (en) 2013-03-14 2022-05-31 Janssen Pharmaceutica Nv Gpr120 agonists for the treatment of type ii diabetes
AP2016009176A0 (en) 2013-11-14 2016-04-30 Cadila Healthcare Ltd Novel heterocyclic compounds
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
MX2020008404A (es) 2018-02-13 2020-09-25 Gilead Sciences Inc Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CN110590767B (zh) * 2019-08-29 2021-10-08 南方科技大学 一种合成amg837的方法
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
EP4153589A1 (en) 2020-05-19 2023-03-29 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
CA2520114A1 (en) 2003-04-04 2004-10-21 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
JP2007510662A (ja) 2003-11-04 2007-04-26 エリクシアー ファーマシューティカルズ， インコーポレイテッド 治療化合物およびその使用
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
AU2005280921B2 (en) * 2004-09-07 2011-05-19 Msd K.K. Carbamoyl-substituted spiro derivative
CN101553493B (zh) * 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途
JPWO2008038692A1 (ja) * 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
ATE486877T1 (de) * 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
US7572934B2 (en) * 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
TWI421070B (zh) 2007-10-26 2014-01-01 Japan Tobacco Inc 螺化合物及其醫藥用途
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament

Also Published As

Publication number Publication date
CR20120296A (es) 2012-07-16
MA33840B1 (fr) 2012-12-03
AR078948A1 (es) 2011-12-14
ZA201203055B (en) 2013-09-25
GT201200164A (es) 2014-02-27
AU2010324987A1 (en) 2012-07-26
TW201141866A (en) 2011-12-01
MX2012006233A (es) 2012-07-03
BR112012012903A2 (pt) 2017-03-01
WO2011066183A1 (en) 2011-06-03
EP2507228B1 (en) 2014-11-05
NZ600203A (en) 2013-09-27
AU2010324987B2 (en) 2014-01-30
EA020507B1 (ru) 2014-11-28
JP5709889B2 (ja) 2015-04-30
CN102648195B (zh) 2015-01-07
EP2507228A1 (en) 2012-10-10
IL219594A0 (en) 2012-06-28
PE20121474A1 (es) 2012-11-05
CL2012001321A1 (es) 2013-11-15
JP2013512277A (ja) 2013-04-11
TN2012000248A1 (en) 2013-12-12
CA2781292A1 (en) 2011-06-03
CN102648195A (zh) 2012-08-22
KR20120088770A (ko) 2012-08-08
US20120220616A1 (en) 2012-08-30
US8822486B2 (en) 2014-09-02
EA201290416A1 (ru) 2012-11-30
KR101410103B1 (ko) 2014-06-25
CA2781292C (en) 2014-04-22
ES2526568T3 (es) 2015-01-13
DOP2012000139A (es) 2012-08-15

Similar Documents

Publication Publication Date Title
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
UY32062A (es) Inhibidores de beta-secretasa
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
GT201400022A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
IN2014KN00948A (es)
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
CL2014001154A1 (es) Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana.
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CR20140325A (es) Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2-
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
CL2013002584A1 (es) Compuestos derivados de 2-(2-metilpropanoil)pirazolidin-3-carboxamida, inhibidores de la peptido desformilasa (pdf); composición farmaceutica, utiles en el tratamiento de una infeccion bacteriana.
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
AR080025A1 (es) Derivados de 8-aza-biciclo[3,2,1] oct-3-iloxi)-cromen-2-ona, utiles como inhibidores de la recaptacion del neurotransmisor monoamina
CO6382120A2 (es) Compuestos ciclopropilo
CL2011000120A1 (es) Proceso de preparacion de compuestos 2-amino-tiazolonas sustituidas.
MX2013006185A (es) Compuestos de 6-(piridinilmetoxi) -pirrolopiridina 3-sustituidos.
CL2007003806A1 (es) Compuestos derivados de n-(2h-pirazol-3-il)-amida, inhibidores del fgfr; composicion farmaceutica que comprende a dichos compuestos; su proceso de preparacion; y su uso para el tratamiento del cancer.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.